A detailed history of Palo Alto Investors LP transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 6,391,775 shares of GOSS stock, worth $5.75 Million. This represents 0.88% of its overall portfolio holdings.

Number of Shares
6,391,775
Previous 5,958,888 7.26%
Holding current value
$5.75 Million
Previous $5.42 Million 39.1%
% of portfolio
0.88%
Previous 0.5%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.8 - $1.51 $346,309 - $653,659
432,887 Added 7.26%
6,391,775 $7.54 Million
Q4 2023

Feb 15, 2024

BUY
$0.48 - $1.08 $1.2 Million - $2.69 Million
2,493,736 Added 71.97%
5,958,888 $5.42 Million
Q4 2023

Feb 14, 2024

SELL
$0.48 - $1.08 $1.47 Million - $3.31 Million
-3,065,136 Reduced 46.94%
3,465,152 $3.15 Million
Q3 2023

Nov 14, 2023

BUY
$0.78 - $1.82 $2.39 Million - $5.58 Million
3,065,136 Added 88.46%
6,530,288 $5.42 Million
Q1 2023

May 15, 2023

BUY
$0.96 - $2.92 $3.29 Million - $10 Million
3,427,402 Added 9079.21%
3,465,152 $4.37 Million
Q4 2022

Feb 14, 2023

SELL
$1.74 - $12.87 $2.98 Million - $22 Million
-1,712,901 Reduced 97.84%
37,750 $81,000
Q2 2022

Aug 15, 2022

SELL
$5.97 - $9.97 $36,452 - $60,876
-6,106 Reduced 0.35%
1,750,651 $14.7 Million
Q1 2022

May 16, 2022

SELL
$8.44 - $12.49 $136,668 - $202,250
-16,193 Reduced 0.91%
1,756,757 $15.2 Million
Q1 2021

May 17, 2021

BUY
$8.63 - $10.94 $292,557 - $370,866
33,900 Added 1.95%
1,772,950 $16.4 Million
Q4 2020

Feb 16, 2021

BUY
$8.3 - $13.59 $5.49 Million - $8.99 Million
661,850 Added 61.44%
1,739,050 $16.8 Million
Q3 2020

Nov 16, 2020

BUY
$11.3 - $14.75 $9.86 Million - $12.9 Million
872,986 Added 427.49%
1,077,200 $13.4 Million
Q2 2020

Aug 14, 2020

BUY
$9.52 - $15.98 $1.94 Million - $3.26 Million
204,214 New
204,214 $2.66 Million

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $84.6M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Palo Alto Investors LP Portfolio

Follow Palo Alto Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.